Johnson & Johnson has discontinued a phase 2 trial of one of its pipeline candidates for atopic dermatitis (AD), after it failed to meet efficacy expectations. In a statement, J&J said that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results